These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30561229)

  • 1. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.
    Ghil J; Zielińska A; Lee Y
    Curr Med Res Opin; 2019 Mar; 35(3):497-502. PubMed ID: 30561229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis.
    Rho YH; Rychlewska-Hańczewska A; Śliwowska B; Kim TH
    Adv Ther; 2019 Sep; 36(9):2287-2295. PubMed ID: 31372961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
    Shin D; Lee Y; Jeong D; Ellis-Pegler R
    Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE
    Cohen S; Klimiuk PA; Krahnke T; Assudani D
    Expert Opin Drug Deliv; 2018 Jun; 15(6):545-548. PubMed ID: 29764238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
    Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
    Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
    Cox DS; Alvarez DF; Bock AE; Cronenberger CL
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1166-1173. PubMed ID: 33765358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
    Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
    Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
    Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
    Bush J; Kawakami K; Muniz R
    BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
    Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
    Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
    Yu KS; Ryu H; Shin D; Park M; Hwang J; Moon SJ; Kim MG; Keystone E; Smolen JS; Kim S; Bae Y; Jeon D; Jang J; Yang G; Bae J; Lee J; Burmester GR
    Expert Opin Biol Ther; 2024 Jul; 24(7):681-689. PubMed ID: 38905143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17.
    Viapiana O; Lee S; Yoon S; Fautrel B
    Clin Drug Investig; 2022 Feb; 42(2):103-112. PubMed ID: 35025072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
    Müller-Ladner U; Dignass A; Gaffney K; Jadon D; Matucci-Cerinic M; Lobaton T; Carron P; Gisbert JP; Pande I; Utzinger M; Addison J
    BioDrugs; 2023 Nov; 37(6):873-889. PubMed ID: 37632666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
    von Richter O; Lemke L; Haliduola H; Fuhr R; Koernicke T; Schuck E; Velinova M; Skerjanec A; Poetzl J; Jauch-Lembach J
    Expert Opin Biol Ther; 2019 Oct; 19(10):1075-1083. PubMed ID: 30698045
    [No Abstract]   [Full Text] [Related]  

  • 15. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects.
    Sabet A; Dickerson DS; Kunina EE; Buccarello AL; Monnet J
    Rheumatol Ther; 2022 Apr; 9(2):693-704. PubMed ID: 35262901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
    Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
    Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).
    Cohen SB; Czeloth N; Lee E; Klimiuk PA; Peter N; Jayadeva G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1097-1105. PubMed ID: 31387417
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe.
    Damjanov N; Kirvalidze N; Kurashvili N; Berti F; Steiger M; Sobierska J; Guenzi E; Otto H; Sattar A; Haliduola HN; Edwald E; Stroissnig H
    Expert Opin Biol Ther; 2023; 23(8):781-789. PubMed ID: 36205514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
    Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
    J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.